|
Eisai is appalled by arbitrary decision to remove life-extending breast cancer therap
Eisai has announced its extreme disappointment that the National Cancer Drugs Fund(NCDF) panel has apparently made the decision to remove Halaven(R) (eribulin) from theCancer Drugs Fund (CDF)...
More... |
| All times are GMT -7. The time now is 03:15 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021